These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37909133)

  • 21. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
    Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
    Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo.
    Bergamaschi C; Jalah R; Kulkarni V; Rosati M; Zhang GM; Alicea C; Zolotukhin AS; Felber BK; Pavlakis GN
    J Immunol; 2009 Sep; 183(5):3064-72. PubMed ID: 19696432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation.
    Ota N; Takase M; Uchiyama H; Olsen SK; Kanagawa O
    J Immunol; 2010 Nov; 185(10):6041-8. PubMed ID: 20926799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of interleukin-15 for higher E. coli expression and solubility.
    Béhar G; Solé V; Defontaine A; Maillasson M; Quéméner A; Jacques Y; Tellier C
    Protein Eng Des Sel; 2011 Mar; 24(3):283-90. PubMed ID: 21109548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IRF-1 promotes liver transplant ischemia/reperfusion injury via hepatocyte IL-15/IL-15Rα production.
    Yokota S; Yoshida O; Dou L; Spadaro AV; Isse K; Ross MA; Stolz DB; Kimura S; Du Q; Demetris AJ; Thomson AW; Geller DA
    J Immunol; 2015 Jun; 194(12):6045-56. PubMed ID: 25964490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
    Votavova P; Tomala J; Kovar M
    Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contributions of interfacial residues of human Interleukin15 to the specificity and affinity for its private alpha-receptor.
    Sakamoto S; Caaveiro JM; Sano E; Tanaka Y; Kudou M; Tsumoto K
    J Mol Biol; 2009 Jun; 389(5):880-94. PubMed ID: 19406127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.
    Robinson TO; Hegde SM; Chang A; Gangadharan A; Rivas S; Madakamutil L; Zalevsky J; Miyazaki T; Schluns KS
    J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of different forms of IL-15 in human melanoma progression.
    Di Matteo S; Munari E; Fiore PF; Santopolo S; Sampaoli C; Pelosi A; Chouaib S; Tumino N; Vacca P; Mariotti FR; Ebert S; Machwirth M; Haas D; Pezzullo M; Pietra G; Grottoli M; Buart S; Mortier E; Maggi E; Moretta L; Caruana I; Azzarone B
    Front Immunol; 2023; 14():1183668. PubMed ID: 37334356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-15Rα is a determinant of muscle fuel utilization, and its loss protects against obesity.
    Loro E; Seifert EL; Moffat C; Romero F; Mishra MK; Sun Z; Krajacic P; Anokye-Danso F; Summer RS; Ahima RS; Khurana TS
    Am J Physiol Regul Integr Comp Physiol; 2015 Oct; 309(8):R835-44. PubMed ID: 26269523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic and Structural Insights on the IL-15 System through Molecular Dynamics Simulations.
    Sousa RP; Laurent AD; Quéméner A; Mortier E; Questel JL
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31500206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells.
    Sato N; Patel HJ; Waldmann TA; Tagaya Y
    Proc Natl Acad Sci U S A; 2007 Jan; 104(2):588-93. PubMed ID: 17202253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequencies of IL-15Rα+ cells in patients with Behçet's disease and the effects of overexpressing IL-15Rα+ on disease symptoms in mice.
    Islam SMS; Choi B; Choi J; Lee ES; Sohn S
    Cytokine; 2018 Oct; 110():257-266. PubMed ID: 29396044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different NK cell developmental events require different levels of IL-15 trans-presentation.
    Lee GA; Liou YH; Wang SW; Ko KL; Jiang ST; Liao NS
    J Immunol; 2011 Aug; 187(3):1212-21. PubMed ID: 21715685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docking of human interleukin-15 to its specific receptor alpha chain: correlation between molecular modeling and mutagenesis experimental data.
    Quéméner A; Bernard J; Mortier E; Plet A; Jacques Y; Tran V
    Proteins; 2006 Nov; 65(3):623-36. PubMed ID: 17001647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man.
    Bouchaud G; Gehrke S; Krieg C; Kolios A; Hafner J; Navarini AA; French LE; Boyman O
    J Exp Med; 2013 Sep; 210(10):2105-17. PubMed ID: 24019554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors.
    Żyżyńska-Granica B; Trzaskowski B; Niewieczerzał S; Filipek S; Zegrocka-Stendel O; Dutkiewicz M; Krzeczyński P; Kowalewska M; Koziak K
    Eur J Med Chem; 2017 Aug; 136():543-547. PubMed ID: 28535470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα.
    Sato N; Sabzevari H; Fu S; Ju W; Petrus MN; Bamford RN; Waldmann TA; Tagaya Y
    Blood; 2011 Apr; 117(15):4032-40. PubMed ID: 21304101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
    Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
    Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.
    Zong M; Loell I; Lindroos E; Nader GA; Alexanderson H; Hallengren CS; Borg K; Arnardottir S; McInnes IB; Lundberg IE
    Ann Rheum Dis; 2012 Jun; 71(6):1055-63. PubMed ID: 22267334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.